parathyroid gland, medullothyroid gland, and pancreas f3 cells), l,25-dihydroxyvitamin D, and enzymes are involved (3,4). Moreover, arteriosclerosis and atherosclerosis are calcium-dependent (3, 5). In IDD women, the significant negative correlation between P1-Ca and total cholesterol might be accounted for by the internalization of the calcium or even the cholesterol in the artery wall at a younger age, depending on whether cholesterol or calcium increased in their plasma. Thus, an increase in plasma cholesterol could allow P1-Ca to penetrate into the artery intima, to form atherosclerotic plaques in patients for whom atherosclerosis is very common and occurs early (4). The Bogalusa Heart Study (Framingham Junior survey) has just provided additional proof that cholesterol is one, if not the major, cause of atherosclerosis (6) . Could calcium be the missing piece in this puzale of atherosclerotic plaque formation?
Once again, biological results are not the same for both sexes (2) (3) (4) . The epidemiologic, clinical, ergometric, and therapeutic particularities of women presenting with coronary insufficiency have just been described (7). Our results raise questions that were not resolved in that study, and suggest that much work remains to be done. 
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To the Editor:
Although several studies have been recently published concerning assay of endogenous digoxin-like immunoreactive substance(s) (Dus) in human body fluids (1-6), and the putative endogenous substance has been almost partially purified and identified (7), there is no accord on the nomenclature (ous, DLF, OLF, Endoxin, Endaline, etc.) and the best procedure(s) of sample collection, storage, and assay. This lack of standardization not only generates confusion, but also can be the cause of discordant results and erroneous findings. The aim of this Letter is to discuss some methodological points of mis assay, adding personal contributions, in order to stimulate a more general discussion among the groups interested in studies concerning endogenous cardiac glycosides-like substances.
Sample preparation-Several authors (8) (9) (10) (11) (12) (13) 14) . This procedui-e seems preferable when radioreceptor assay (RRA) and (or) transmembrane ion-transport studies are used with the ifiA for detection of cardiac glycosides-like compounds. In fact, by loading the sample through the column, washing it with 40 mL of distilled water, and eluting the plasma extracts with methanol it is possible to remove the ions and proteins and avoid this kind of interferences in RRA or transmembrane iontransport methods (14). This procedure is rapid and the mean recovery was 82% (14) .
On the other hand, we think that a direct assay (without sample extraction and concentration) should be used when plasma samples from newborns, pregnant women, and patients with renal or liver disease are assayed, because of their higher mis concentrations in plasma in comparison with normal adult subjects (2, 3, 5) . In addition, urine samples from adults and newborns have DLIS concentrations four to six times higher than those in plasma samples, so also in this case the direct RIA seems preferable, as we have previously reported (5, 15).
Sample storage-There are no data in the literature on stability of DLIS during storage. In our laboratory, two pools (A and B) of urine from newborns were stored in various 1-mL aliquots at -20 #{176}C and assayed by RIA for 17 months. Only pool A demonstrated a significant decrease in immunoreactivity during this interval (Figure 1 ). This discrepancy was probably ascribable to the higher imprecision for assay of pool B (CV about 22% vs 18%). The decay of digoxin-like immunoreactivity was, however, very small (about 1% per month) and, also for pool A, a significant decrease of mis was not detectable before eight months of storage at -20 #{176}C. Evidently DLIS can be validly measured in urine samples stored for some months at -20 #{176}C. Unfortunately, at present we have no definitive data on the stability of mis in serum (plasma) pools. We directly (i.e., without extraction) assayed, during 10 months, a pool of plasma from blood donors, but the very low DLIS concentration, about 15 ng/L, did not permit a significant statistical analysis because of the high imprecision of the assay (CV >40%). Pooled plasma from newborns, from pregnant women, or from patients with renal diseases, with higher than normal DLIS concentrations, could be used to test the stability of digitalis-like immunoreactivity in plasma.
Preparation of standard curve-Most authors who have measured DLIS with RIA or enzyme immunoassay methods have used commercial kits and performed the assay as suggested by the manufacturers.
In commercial kits for digoxin assay, digoxin added to human plasma (or serum) is generally used as standard. We have previously demonstrated (5, 11, 15 ) that, in normal plasma, low but measurable amounts of digoxin-like substance(s) are present. Using a RIA kit with serum standards for DLIS assay (SPAC Digoxin; Mallinckrodt, Dietzenbach, F.R.G.) we have found that most (>70% in two different assays) plasma samples (direct assay) with mis concentrations within the normal range (0-35 ngIL) have a bound radioactivity higher than that of the B0 standard. Therefore, it is important to test for the presence of significant amounts of DLIS in the serumbasal standards used for the calibration curve. To avoid this kind of interference we recommend the use of buffer solutions containing standard digoxin and human serum albumin (11, 15) or low-molecular-mass-deprived human serum as standard for calibration curves.
Immunological and biological activity-Because the chemical nature of DUS is not yet known, it is not possible to perform specific RIA assays for mis by use of specific antisera against DLIS, with DLIS as standard. The relatively poor specificity of measurement of DLIS with digoxin RIA kits makes it possible that substances with biological activity similar to cardiac glycosides are not detected by digoxin RIA methods. For example, ouabain, a compound that strongly inhibits Na/K ATPase activity, does not significantly interfere in our digoxin RIA system (11). On the other hand, it is also possible that several compounds interfering in the RIA system do not share any biological activity (12, 16, 17) 
Measurement of Stable Glycated Hemoglobin
To the Editor:
In view of the concern regarding the effect of the labile Schiff base adduct (pre-Hb A1) on the true values for Hb A1 as measured by cation-exchange chromatography (1, 2), we report the simple method used routinely in our laboratory to remove pre-Hb A1.
Hb A1 was measured in one normal subject and eight diabetic patients by use of a medium-sized chromatographic column containing Bio-Rex 70 cation-exchange resin (3). Blood was collected with EIYFA as anticoagulant, and samples were variously treated as below before the hemolysates were pre-(a) Hb A1 was measured immediately after the blood was drawn.
(b) Whole anticoagulated blood (1.5 mL) was pipetted into 8.5 mL of isotonic saline in a tube, mixed several times with gentle inversion, then centrifuged (10 mm, 3000 rpm) and the supernate was discarded. A second 8.5-mL allquot of isotonic saline was added to the sedimented erythrocytes, mixed by gentle inversion until all the cells were in suspension. The tube was then centrifuged and the supernatant fluid was again discarded. We then added 8.5 mL of saline to the washed erythrocytes, mixed well by gentle inversion until all the cells were in suspension, then incubated at 37 #{176}C for 6 h in a shaking
